Clostridium difficile recurrence is characterized by pro-inflammatory peripheral blood mononuclear cell (PBMC) phenotype

Mary B. Yacyshyn,1 Tara N. Reddy,2 Lauren R. Plageman,1 Jiang Wu,2 Amy R. Hollar1 and Bruce R. Yacyshyn1

1Division of Digestive Diseases, Department of Medicine, University of Cincinnati, Cincinnati, Ohio, USA
2Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA

INTRODUCTION

In 2008, the Infectious Diseases Society of America (IDSA) issued notification of a forthcoming epidemic of antibiotic resistant infections (Spellberg et al., 2008). In their 2013 report, the United States Centers for Disease Control and Prevention (CDC) singled out Clostridium difficile infection (CDI) as one of three urgent health threats due to overuse and antibiotic resistance (CDC, 2013). At the time of writing, it is estimated that 250 000 people will contract CDI and 14 000 will die this year from the infection. The cost of this infection to the healthcare system will be over one billion dollars annually (Spellberg et al., 2008). To curb the growth and cost of CDI, we need to better understand how the host responds and what constitutes the most productive form of response, including both humoral and cellular arms of immunity.

The clostridial species are involved in education of the immune system as well as contributing to the homeostasis of the intestinal tract (Atarashi et al., 2011; Chiba & Seno, 2011; Gaboriau-Routhiau et al., 2009). Naturally occurring toxigenic C. difficile can be found in 1–3 % of adults while both non-toxigenic and toxigenic forms transiently colonize 70–100 % of infants during their first year of life (Adlerberth et al., 2014; Rousseau et al., 2012). The optimal response for clearing CDI requires both humoral and cellular immunity (Kelly & Kyne, 2011; Madan & Petri, 2012). It is known that recurrent CDI patients produce a diminished humoral response to both toxin and non-toxigenic antigens (Kelly, 2012; Madan & Petri, 2012; Péchine et al., 2007; Yacyshyn & Yacyshyn, 2013). In a recent publication, increased levels of faecal IL8 and CXCL-5, markers of intestinal inflammation, demonstrated greater correlation to remitting or persistent CDI than to bacterial burden (El Feghaly et al., 2013a, b). Hence previous studies suggest that recurrent CDI patients’ immune response is less than optimal for bacterial clearance and potentially skewed.

Abbreviations: CDI, Clostridium difficile infection; PBMC, peripheral blood mononuclear cell(s); Treg, T regulatory; SOC, standard of care; SSC, side scatter; WBC, white blood cell.
towards producing intestinal inflammation. We hypothesized that recurrent patients produce a greater proinflammatory response during CDI, which could be detected in the Th17, Th1 and T-regulatory (Treg) subsets circulating in their peripheral blood mononuclear cells (PBMC).

**METHODS**

**Patients with* C. difficile*: inclusion/exclusion criteria.** All patients positive for* C. difficile* were reviewed at the University of Cincinnati hospital between Jan 2011 and Sept 2012. Inclusion criteria: adults at least 18 years of age, have had at least one ELISA + toxin test or a positive loop-mediated isothermal amplification (LAMP) test within 72 h, and agreed informed consent. All had started standard of care (SOC) therapy, either metronidazole or vancomycin. Exclusion criteria: patients having cancer, on chemotherapy, taking any immunosuppressive, major surgery within 6 weeks, HIV + or any chronic GI inflammatory disease.

**Definitions.** Initial CDI was defined as new onset of diarrhoea (≥3 loose stools day⁻¹ for more than 24 h), at least one positive laboratory test and no other* C. difficile* positive test within 1 year of surveillance. This patient group hereafter is referred to as ‘initial’. Recurrent CDI was defined as recurrence or onset of new diarrhoea after a symptom-free period of ≥3 days and completion of at least one round of SOC therapy. We consented 32 patients at the point of new onset CDI. Six of these patients became recurrent and hereafter are referred to as ‘became recurrent’. Due to excluding over 50% of CDI patients for factors previously mentioned and a set timeline for patient enrolment, we included these six CDI patients in the recurrent group. Upon initial analysis, it was apparent that those patients who ‘became recurrent’ (6 CDI patients) were different from the ‘known recurrent’ patients (14 CDI patients). Case controls were comorbid and hospitalized patients who had diarrhoea and were tested for CDI but were negative and remained negative over the 1 year follow up. Over the course of patient enrolment, two types of toxin tests were used. From November 2010 to August 2011, the enzyme immunoassay for toxins A and B was used. From August 2011 on, the Meridian Illumigene for* C. difficile* was used. Healthy controls were...

### Table 1. Patient demographics

Patient demographics were collected and recorded on day of consent.

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Healthy control (n=16)</th>
<th>Case control (n=20)</th>
<th>Initial CDI (n=20)</th>
<th>Recurrent CDI (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean)</td>
<td>48.43</td>
<td>52.8</td>
<td>59.80</td>
<td>52.90</td>
</tr>
<tr>
<td>Age (range)</td>
<td>30–62</td>
<td>25–77</td>
<td>30–79</td>
<td>33–84</td>
</tr>
<tr>
<td>Proportion of group with age ≥65 (%)</td>
<td>0</td>
<td>25</td>
<td>45</td>
<td>25</td>
</tr>
<tr>
<td>Female gender</td>
<td>81% (14/16)</td>
<td>70% (14/20)</td>
<td>55% (11/20)</td>
<td>60% (12/20)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>16</td>
<td>11</td>
<td>13</td>
<td>11</td>
</tr>
<tr>
<td>African American</td>
<td>0</td>
<td>9</td>
<td>7</td>
<td>9</td>
</tr>
</tbody>
</table>

**Table 2. Patient comorbidities**

Patient histories were recorded on the day of consent. Patients could have complex histories with more than one comorbidity associated with a system. However, for ease of representation and comparison the comorbidities were aggregated and counted as one in each system.

<table>
<thead>
<tr>
<th>System</th>
<th>Healthy control (%) (n=16)</th>
<th>Case control (%) (n=20)</th>
<th>Initial CDI (%) (n=20)</th>
<th>Recurrent CDI (%) (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>6.2 (1/16)</td>
<td>75 (15/20)</td>
<td>70 (14/20)</td>
<td>70 (14/20)</td>
</tr>
<tr>
<td>Endocrine</td>
<td>6.2 (1/16)</td>
<td>70 (14/20)</td>
<td>60 (12/20)</td>
<td>55 (11/20)</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>18.8 (3/16)</td>
<td>65 (13/20)</td>
<td>70 (14/20)</td>
<td>80 (16/20)</td>
</tr>
<tr>
<td>Haematology/oncology</td>
<td>0 (0/16)</td>
<td>5 (1/20)</td>
<td>15 (3/20)</td>
<td>10 (2/20)</td>
</tr>
<tr>
<td>Anaemia</td>
<td>0 (0/16)</td>
<td>20 (4/20)*</td>
<td>25 (5/20)</td>
<td>55 (11/20)</td>
</tr>
<tr>
<td>Infection (non- C. difficile)</td>
<td>0 (0/16)</td>
<td>30 (6/20)</td>
<td>25 (5/20)</td>
<td>35 (7/20)</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>25 (4/16)</td>
<td>20 (4/20)</td>
<td>25 (5/20)</td>
<td>30 (6/20)</td>
</tr>
<tr>
<td>Neurological</td>
<td>6.2 (1/16)</td>
<td>35 (7/20)</td>
<td>25 (5/20)</td>
<td>35 (7/20)</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>6.2 (1/16)</td>
<td>35 (14/20)</td>
<td>35 (7/20)</td>
<td>45 (9/20)</td>
</tr>
<tr>
<td>Rheumatoid</td>
<td>12.5 (2/16)</td>
<td>5 (1/20)†</td>
<td>10 (2/20)</td>
<td>35 (7/20)</td>
</tr>
<tr>
<td>Respiratory</td>
<td>18.8 (3/16)</td>
<td>35 (7/20)</td>
<td>40 (8/20)</td>
<td>65 (13/20)</td>
</tr>
<tr>
<td>Urinary tract or kidney</td>
<td>0 (0/16)</td>
<td>60 (12/20)$§$</td>
<td>25 (5/20)</td>
<td>20 (4/20)</td>
</tr>
<tr>
<td>Age-adjusted Charlson comorbidity index</td>
<td>3.05</td>
<td>3.9</td>
<td>3.9</td>
<td>3.9</td>
</tr>
</tbody>
</table>

*Case control vs recurrent CDI P = 0.048.
†Case control vs recurrent CDI P=0.0436.
§Case control vs recurrent CDI P=0.022.
$Case control vs initial CDI P = 0.053.
healthy individuals who were asked and consented to give blood, medical history and concomitant medications.

Patient medical history and concomitant medications. The history and medication lists of each patient were recorded on the day of consent and blood was drawn. We amalgamated over 100 different medical diagnoses and allocated them amongst 13 systemic medical systems. Case controls and initial patients exhibited a mean of nine different medical diagnoses, while the recurrent population exhibited a mean of 10. Almost 150 different concomitant medications were incorporated into a list resulting in 23 top medication classes. All three patient groups of representation and comparison of groups, these were aggregated and counted as one for each category.

Table 3. Patient concomitant medications

<table>
<thead>
<tr>
<th>Drug category</th>
<th>Healthy control (%) (n=16)</th>
<th>Case control (%) (n=20)</th>
<th>Initial CDI (%) (n=20)</th>
<th>Recurrent CDI (%) (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitor</td>
<td>0 (0/16)</td>
<td>25 (5/20)</td>
<td>30 (6/20)</td>
<td>20 (4/20)</td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>6.2 (1/16)</td>
<td>60 (12/20)</td>
<td>35 (7/20)</td>
<td>35 (7/20)</td>
</tr>
<tr>
<td>Probiotic</td>
<td>0 (0/16)</td>
<td>20 (4/20)</td>
<td>25 (5/20)</td>
<td>40 (8/20)</td>
</tr>
<tr>
<td>Proton pump inhibitor</td>
<td>18.8 (3/16)</td>
<td>55 (11/20)</td>
<td>70 (14/20)</td>
<td>55 (11/20)</td>
</tr>
<tr>
<td>Statin</td>
<td>0 (0/16)</td>
<td>50 (10/20)</td>
<td>20 (4/20)</td>
<td>30 (6/20)</td>
</tr>
<tr>
<td>Allergy medications</td>
<td>6.2 (1/16)</td>
<td>30 (6/20)</td>
<td>25 (5/20)</td>
<td>20 (4/20)</td>
</tr>
<tr>
<td>Anti-epileptics</td>
<td>6.2 (1/16)</td>
<td>40 (8/20)</td>
<td>35 (7/20)</td>
<td>30 (6/20)</td>
</tr>
<tr>
<td>Blood thinner</td>
<td>6.2 (1/16)</td>
<td>65 (13/20)</td>
<td>65 (13/20)</td>
<td>60 (12/20)</td>
</tr>
<tr>
<td>Diuretic</td>
<td>6.2 (1/16)</td>
<td>15 (3/20)</td>
<td>35 (7/20)</td>
<td>25 (5/20)</td>
</tr>
<tr>
<td>Narcotics</td>
<td>6.2 (1/16)</td>
<td>45 (9/20)</td>
<td>40 (8/20)</td>
<td>60 (12/20)</td>
</tr>
<tr>
<td>Pain (non-narcotic)</td>
<td>12.5 (2/16)</td>
<td>30 (6/20)</td>
<td>30 (6/20)</td>
<td>20 (4/20)</td>
</tr>
<tr>
<td>Stool laxative</td>
<td>6.2% (1/16)</td>
<td>45% (9/20)</td>
<td>25% (5/20)</td>
<td>10% (2/20)*</td>
</tr>
<tr>
<td>SSRI/SNRI†</td>
<td>25% (4/16)</td>
<td>35% (7/20)</td>
<td>30% (6/20)</td>
<td>25% (5/20)</td>
</tr>
<tr>
<td>Thyroid medications</td>
<td>6.2% (1/16)</td>
<td>35% (7/20)</td>
<td>10% (2/20)</td>
<td>20% (4/20)</td>
</tr>
<tr>
<td>Antibiotics/antifungals</td>
<td>0% (0/16)</td>
<td>40% (8/20)</td>
<td>100% (20/20)</td>
<td>100% (20/20)</td>
</tr>
<tr>
<td>Anti-emetic</td>
<td>0% (0/16)</td>
<td>45% (9/20)</td>
<td>25% (5/20)</td>
<td>25% (5/20)</td>
</tr>
<tr>
<td>Anti-psychotic</td>
<td>0% (0/16)</td>
<td>20% (4/20)</td>
<td>15% (3/20)</td>
<td>10% (2/20)</td>
</tr>
<tr>
<td>Benzodiazepine</td>
<td>0% (0/16)</td>
<td>45% (9/20)</td>
<td>30% (6/20)</td>
<td>35% (7/20)</td>
</tr>
<tr>
<td>Insulin</td>
<td>0% (0/16)</td>
<td>50% (10/20)</td>
<td>35% (7/20)</td>
<td>45% (9/20)</td>
</tr>
<tr>
<td>Gastrointestinal prokinetic</td>
<td>0% (0/16)</td>
<td>20% (4/20)</td>
<td>25% (5/20)</td>
<td>15% (3/20)</td>
</tr>
<tr>
<td>Non-steroidal anti-inflammatory drugs (NSAIDs)</td>
<td>25% (4/16)</td>
<td>0% (0/20)</td>
<td>5% (1/20)</td>
<td>5% (1/20)</td>
</tr>
<tr>
<td>Respiratory medication</td>
<td>0% (0/16)</td>
<td>45% (9/20)</td>
<td>40% (8/20)</td>
<td>40% (8/20)</td>
</tr>
<tr>
<td>Vitamins/minerals</td>
<td>43.7% (7/16)</td>
<td>60% (12/20)</td>
<td>70% (14/20)</td>
<td>75% (15/20)</td>
</tr>
</tbody>
</table>

*P<0.05 Recurrent vs case controls.
†Selective serotonin reuptake inhibitors/serotonin–norepinephrin reuptake inhibitors.
‡P<0.0001 Recurrent vs case control and initial vs case control.

RESULTS

Patient demographics

Thirty-two patients who presented with initial CDI were consented and entered the study. Six patients were later
excluded for other reasons, leaving 26 initial CDI patients. However, 6 of the 26 initial CDI patients became recurrent within 1–3 months, giving us an approximate 19% recurrence rate during our study. A further 14 recurrent patients were consented upon presentation of new diarrhoea after a symptom-free period of $\geq$ 3 days and completion of at least one round of SOC therapy. Twenty-one comorbid case controls (CDI negative) were consented and 20 entered the study. Sixteen healthy controls were also consented and included in the study. General age, gender and race distribution can be seen in Table 1. Patients’ comorbidities are found in Table 2. More of the recurrent population presented with anaemia and rheumatoid comorbidities. The case controls appeared to have more urinary tract or kidney problems. In Table 3, we illustrate the wide variations in patient concomitant medications. The mean number of current medications per patient group was 14, ranging from 6 to 30 medications for individuals. Several patients had complex medication profiles, with multiple medications in a single class. However, for representation, these were aggregated and only counted as one. Interestingly, more case controls were on laxatives.

**Quantitative PBMC differences**

Hospitalized CDI patients can present with increased white blood count due to acute infection (Bulusuet al., 2000; Planche, 2013). Since our original goal was to determine if
Healthy controls 100 (a) (b) (c) (d) (e) (f) 90 $P = 0.0077$ $P = 0.0025$ $P = 0.0458$ 70 60 50 40 30 20 10 0 Case controls Initial C. difficile Recurrent Became recurrent C. difficile Known recurrent C. difficile Healthy controls 100 $P = 0.05$ $P = 0.04$ $P = 0.02$ $P = 0.04$ $P = 0.05$ 80 70 60 50 40 30 20 10 0 Case controls Initial C. difficile Recurrent Became recurrent C. difficile Known recurrent C. difficile Healthy controls 100 $P = 0.014$ $P = 0.009$ $P = 0.009$ 80 70 60 50 40 30 20 10 0 Case controls Initial C. difficile Recurrent Became recurrent C. difficile Known recurrent C. difficile Healthy controls 100 $P = 0.048$ $P = 0.023$ 20 15 10 5 0 10 20 30 40 50 60 70 80 90 100 Case controls Initial C. difficile Recurrent Became recurrent C. difficile Known recurrent C. difficile

M. B. Yacyshyn and others
Fig. 2. Ficoll-purified PBMC were stained for CD3 and CD8, then gated on (a) CD3+ or (d) CD3− cells and then analysed for percentage of CD3+ and CD3− cells along with (b) CD3+CD4+, (c) CD3−CD8+, (e) CD3+CD8− and (f) CD3−CD8+ lymphocytes in gate 1. CD3+CD4+ cells were represented by the CD3+CD8− subset in the CD3+ lymphocyte gate. Statistical analysis was carried out using the non-parametric Wilcoxon rank sum test. Circles and asterisks represent outlier values. All asterisks represent outlier values, which lay outside the box at a distance of 1.5x the box size. All circles represent outlier values greater than the distance of 3x the box size.

Circulating CD3+ and CD3− populations in gate 1

Circulating PMBC from initial CDI patients had a significantly lower percentage of CD3+ lymphocytes when compared with healthy controls (P=0.0077), case controls (P=0.0025) and those patients who became recurrent (P=0.045) (Fig. 2a). Known recurrent CDI patients did not show this significant difference. A ‘box and whisker’ representation of the percentage of CD3+ and CD3− lymphocyte subsets showed broader ranges in the recurrent CDI group when compared with initial CDI, case or healthy controls. Therefore, we decided to subdivide the recurrent population into two smaller subsets because the ‘became recurrent’ CDI subset was distinct. Although this subgroup was very small, it did present us with the opportunity to study phenotypic immune differences at the point of initial infection. We acknowledge that a larger study is needed before any clinical significance can be shown.

CD3+ cells were further subdivided into CD8+ (CD3+CD8+; Fig. 2b) and CD8− (CD3+CD8−; Fig. 2c) populations. Healthy and case controls had significantly more circulating CD3+CD4+ lymphocytes when compared to all groups that were C. difficile positive. CDI patients had fewer CD3+CD4+ PBMC (Fig. 2b). However, CDI patients who became recurrent had significantly more circulating CD3+CD4+ PBMC when compared with the healthy controls (P=0.04) and initial CDI groups (P=0.02; Fig. 2c). The increased CD3+CD8− circulating PMBC suggested that those CDI patients who became recurrent generated an alternative initial response. The case control group also had significantly greater numbers of CD3−CD8+ lymphocytes when compared with initial CDI patients (P=0.03; Fig. 2c). As expected, a higher percentage of CD3− lymphocytes circulated in initial CDI patients’ PMBC when compared with healthy (P=0.014) or case control groups (P=0.009; Fig. 2d). Most CDI patients had significantly more CD3−CD8− lymphocytes than non-CDI case or healthy controls (Fig. 2e). Healthy controls had more CD3−CD8+ circulating lymphocytes in gate 1 (Fig. 2f).

Pro-inflammatory or cell plasticity phenotype of CD3+CD4+ circulating PMBC in CDI recurrence

We hypothesized that recurrent CDI patients would have a greater pro-inflammatory T-cell balance represented by increased circulating Th17 lymphocytes. To examine this, we measured the co-expression of Foxp3 (Treg) or IL17 (Th17) on circulating CD3+CD4+ cells. Although recurrent CDI patients had slightly more CD3+CD4+, which co-expressed Foxp3+ (Fig. 3a), we saw no significant difference between groups. Only healthy controls had significantly fewer CD3+CD4+ IL17+ lymphocytes than any patient group (Fig. 3b). While recurrent patients appear to have a broader range and increased median of IL17+ expressing lymphocytes, the difference did not reach significance. To better demonstrate an individual’s overall inflammatory (more IL17 or IFN-γ) or regulatory (Foxp3) CD3+CD4+ phenotype, we compared co-expression of either Foxp3 or IFN-γ against IL-17 for each individual. The IFN-γ vs IL17 plot (Fig. 3c, lower half) showed 50% of recurrent CDI patients had either a pro-inflammatory CD3+CD4+ phenotype, with increased IFN-γ and IL17 expression (striped circles or diamonds), or predominant IL17 expression (open diamonds). Four other recurrent CDI patients, who did not have increased IFN-γ/IL17 phenotype, had CD3+CD4− phenotypes with higher Foxp3 and IL17 (striped diamonds, upper plot in Fig. 3c). Taken together, circulating CD3+CD4+ cells from recurrent CDI patients were either ‘plastic’ or predominantly pro-inflammatory. This qualitative difference in the circulating PBMC suggested an alternative immune response during recurrent CDI, one that is skewed towards immune plasticity or inflammation. CDI patients who cleared initial infection had circulating CD3+CD4+ lymphocytes more robustly skewed towards Foxp3, Th17 or IFN-γ, with less plasticity in the T-cell response.

Circulating IFN-γ expression

IFN-γ is produced by many different cell types in the innate and adaptive immune response and is a key pro-inflammatory signal (Farrar & Schreiber, 1993; Ishida et al., 2004; Thaiss et al., 2014). We observed IFN-γ expression in CD3+CD4+ (Th1), CD3+CD8− cytotoxic T-lymphocyte (CTL), natural killer T (NKT), CD3−CD8+ (NK) and CD3−CD8− (macrophages, NK) populations. We examined
Two things became apparent: all CD3⁺CD4⁺ and CD3⁺CD8⁺ circulating lymphocytes from healthy persons demonstrated IFN-γ expression while all hospital patients, either CDI-positive or -negative patients, showed broader ranges of IFN-γ expression. This included no expression the CD3⁺IFN-γ⁺ phenotype for each individual (Fig. 4a).
of IFN-γ on CD3+ lymphocytes. Circulating CD3+CD4+ lymphocytes from healthy controls (median of 9.85%) expressed significantly more IFN-γ+ than either initial (P=0.057, median of 7.43%) or known recurrent CDI (P=0.012, median of 6.39%) patients (box and whisker data not shown). PBMC from healthy persons also contained significantly more CD3+CD8+IFN-γ+ cells (median of 11.25%) than known recurrent CDI patients (P=0.044, median of 4.64%, grey diamonds). Those patients who became recurrent had more CD3+CD4+IFN-γ+ cells (median of 15.52%, black circles) than the known recurrent group (P=0.05, median of 4.64%) (box and whisker data not shown).

Less IFN-γ co-expression was found on CD3− cells. Although healthy controls had fewer circulating CD3−CD8− lymphocytes (Fig. 2e), they had significantly greater expression of IFN-γ on their circulating CD3− lymphocytes when compared with case control (P=0.0005, median 0.24%) and initial CDI (P=0.016) groups. Recurrent patients showed increased IFN-γ co-expression on both CD3−CD8− and CD3−CD8+ PBMC when compared with initial CDI and case control groups (Fig. 4b). Known recurrent CDI, initial CDI and case control groups all had significantly less IFN-γ expression on CD3−CD8+ cells when compared with healthy controls (P=0.008, 0.047 and 0.0005, respectively). The case control group of patients had the lowest expression of IFN-γ+ in their CD3− PBMC.

The central role of IFN-γ in the surveillance and protection of a host is demonstrated by the presence of four different IFN-γ+ PBMC populations in the healthy control group. The lack or increase of circulating IFN-γ-co-expressing lymphocytes could be indicative of how the host responds to the infection.
to a pathogen. In this study, five of six CDI patients who became recurrent (black circles in Fig. 4) had increased IFN-γ-co-expressing lymphocytes, indicating a pro-inflammatory (Th1) response at the time of their primary infection.

**Fopx3 expression in circulating CD3− lymphocytes**

CD3−CD4+Foxp3+ cells were clearly visible upon flow cytometry analysis and there was no significant difference between groups (Fig. 3a). However, upon further analysis, we found the CD3− population also expressed Foxp3. The CD3− subset contained several distinct granular populations (based on SSC); therefore, it was further separated into three subsets, high, middle and low (Fig. 5a). Higher background fluorescence was seen as CD3− cell granularity increased and was accounted for in analysis of each population. The most significant difference in CD3−Foxp3+ population between groups was found in the low SSC CD3− subset. This subset was noticeably diminished in recurrent CDI patients (Fig. 5a). Those CDI patients who became recurrent (median CD3− co-expressing Foxp3+ low SSC 2.03 %) were most significantly (P=0.0083) different when compared with the initial CDI patient group (median CD3− co-expressing Foxp3+ low SSC 5.76 %) (box

Fig. 5. Gate 1 PBMC were gated on CD3− cells and plotted showing SSC (representative of the granularity of a cell). (a) Representative flow cytometry plots gated on CD3− lymphocytes and SSC for each group. Recurrent groups have decreased cellular events in low SSC box. (b) The CD3− cells were further gated on high SSC, mid SSC and low SSC. The percentage of cells co-expressing Foxp3 in each of these subsets was calculated. The percentage of mid and low SSC subsets of PBMC co-expressing Foxp3 was plotted for each individual, demonstrating lower Foxp3 expression in the recurrent group. Black circles represent the six patients whose blood was taken at the time of primary CDI, but who later became recurrent.
CDI and its recurrence is a mounting healthcare problem. Understanding host immune responses to this infection will be key to development of non-antibiotic therapies (CDC, 2013; Foglia et al., 2012; Lo Vecchio & Zacur, 2012; Lowy et al., 2010; van Noord et al., 2013; Villano et al., 2012). Most current therapeutic focus revolves around the humoral response. Focus is on boosting the humoral response to toxins, removal of toxins using anti-toxin specific antibodies or altered colonization (Foglia et al., 2012; Lo Vecchio & Zacur, 2012; Lowy et al., 2010; van Noord et al., 2013; Villano et al., 2012). However, the phenotype of the cellular immune response necessary for clearance and protection in CDI patients is less defined (Monaghan et al., 2013). Cellular responses to pathogenic invasion, including CDI, involve both the innate and adaptive immune cells and have been studied using PBMC from healthy persons, but not from CDI patients (Ausiello et al., 2006; Bianco et al., 2011; Jafari et al., 2013; Koon et al., 2013; Mahida et al., 1998; Wu et al., 2013). We examined cellular immune differences between those who productively clear CDI and those who become recurrent. This work complements others that have focused on gut bacterial ecology, colonization and the humoral immune response as factors resulting in CDI (Adlerberth et al., 2014; Martin et al., 2013; Pechine et al., 2007; Rousseau et al., 2012; Villano et al., 2012). We examined the balance of Th1, Treg and Th17 cells in PBMC and are the first, to our knowledge, to demonstrate quantitative and qualitative differences in circulating lymphocytes from those that clear CDI (initial CDI), recurrent CDI cases, comorbid CDI negative case controls and healthy controls.

Using peripheral blood to study systemic effects of local disease has given insights into both the humoral and cellular processes involved in autoimmune and chronic inflammatory diseases (Malmhäll et al., 2012; Monaghan et al., 2013; Omoyinmi et al., 2012; Ueno et al., 2013). Definition of target populations, timing of sample procurement, disease course and severity, age and comorbidities all impact data analysis and comparisons between studies. For example, Bulusu et al. (2000) showed white blood cell WBC counts fluctuate temporally during CDI, and three general patterns of disease course could be discerned. His cohort was male dominated, over 60 years of age, and many had cancer (Bulusu et al., 2000). Lavergne et al. (2013) reported the presence of lymphopenia at the end of SOC treatment for CDI. These authors suggested that the initial T-cell response was not robust and the lymphopenia could be used as a transient biomarker for recurrence (Lavergne et al., 2013). Forty-two per cent of this population was female and the mean age was 77, suggesting that age and immune senescence could also be involved. In our own analysis, we ended up with two distinct recurrent populations. Both represented the standard definition of recurrence but the time of PBMC collection and consent were different. Although this confounded interpretation, subdividing the recurrent group into smaller subgroups for further analysis presented an opportunity for insight into how the immune response differs at the point of primary CDI as well as recurrence. Further study with larger accrual of this key population (primary onset but become recurrent) is needed to determine if this is of clinical significance.

Our primary goal was to examine cellular responses, in particular Th1, Th17 and Treg, and we acknowledge that we excluded up to 50% of CDI patients with cancer, immunosuppression and inflammatory bowel disease. Excluding these patients provided groups more likely to have more similar circulating T-cell populations. Our demographics, which included non-CDI comorbid patients,
indicated we had accrued slightly more females, with mean ages younger than many reported studies. Our population’s trend toward younger age is a reflection of being an urban tertiary care centre with more complicated patients. Furthermore, increasing CDI is found in younger populations in the community. Therefore, our patient cohort provided us the opportunity to study a host’s T-cell phenotype and how it represents a productive cellular immune response to CDI in our current urban environment.

Our CDI patients presented with a WBC range of 5.6 to 24.5 × 10^3 µl^−1, but the composition of isolated PBMC was more indicative of host response to CDI. The circulating PBMC from those who ‘became recurrent’ was different from that of those patients known to be recurrent. Specifically, increased CD3^+ PBMC marked the initial CDI response of six patients who became recurrent, and the percentage of CD3^+CD8^+, not CD3^+CD4^+, was significantly different (Fig. 2).
The percentage of each marker (IL17, Foxp3 or IFN-γ) was calculated as a percentage of total PBMC events collected. Gate 1 represents the cells found in the standard lymphocyte gate. Gate 2 represents the cells found in the standard monocyte gate. Gates 1 + 2 represents over 85% of cells collected in each group. Up to 15% of the cell events collected resided outside of these gates, but formed no other major subset of cells. Spearman rank correlations were used to compare the relationship between pro-inflammatory and regulatory markers in the PBMC.

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Gate</th>
<th>Spearman rank correlation (significant P value)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Foxp3 vs IL17 &amp; IFN-γ</td>
</tr>
<tr>
<td>Healthy controls</td>
<td>Gate 1</td>
<td>0.1562</td>
</tr>
<tr>
<td></td>
<td>Gate 2</td>
<td>0.2310</td>
</tr>
<tr>
<td></td>
<td>Gate 1 + 2</td>
<td>0.2222</td>
</tr>
<tr>
<td>Case controls</td>
<td>Gate 1</td>
<td>0.6386 (0.0030)</td>
</tr>
<tr>
<td></td>
<td>Gate 2</td>
<td>0.5198 (0.0238)</td>
</tr>
<tr>
<td></td>
<td>Gate 1 + 2</td>
<td>0.6772 (0.0019)</td>
</tr>
<tr>
<td>Initial C. difficile</td>
<td>Gate 1</td>
<td>0.0246</td>
</tr>
<tr>
<td></td>
<td>Gate 2</td>
<td>0.4432 (0.0585)</td>
</tr>
<tr>
<td></td>
<td>Gate 1 + 2</td>
<td>0.0193</td>
</tr>
<tr>
<td>Recurrent C. difficile</td>
<td>Gate 1</td>
<td>0.4226</td>
</tr>
<tr>
<td></td>
<td>Gate 2</td>
<td>0.4414 (0.0524)</td>
</tr>
<tr>
<td></td>
<td>Gate 1 + 2</td>
<td>0.4692 (0.0378)</td>
</tr>
</tbody>
</table>

Increased expression of circulating proinflammatory TH17 cells is seen in several immune disorders, including asthma, multiple sclerosis and inflammatory bowel disease (Malmhäll et al., 2012; Ueno et al., 2013). Furthermore, it has recently been demonstrated that pre-exposure to Th17-inducing adjuvant intensifies mucosal inflammation after viral infection (Gopal et al., 2014). Hence, the nature of the initial cellular CDI response and subsequent intestinal or systemic environment will be important to clearance and non-recurrence. Work by El Feghaly et al. (2013a, b) showed markers of intestinal inflammation, not C. difficile burden, predicted outcome of CDI and demonstrated the importance of the inflammatory intestinal environment in CDI clearance. Our study builds on these observations and demonstrates a greater pro-inflammatory balance also exists in circulating PBMC in our recurrent CDI patients. Although the Th17 cell type was originally thought of as a separate lineage, this phenotype can shift towards Th1 or Th2, intensifying the biological process (Cosmi et al., 2014). In CDI, increased IFN-γ production may sustain the inflammatory process. Our data show that the early cellular immune response in those who became recurrent was composed of ≥30% circulating PBMC co-expressing IFN-γ, while ≤20% of circulating PMBC co-expressed IFN-γ in patients who cleared CDI or were already known to be recurrent. Our data are the first, to our knowledge, to demonstrate the importance of early cellular responses to CDI and how the phenotype of CDI patients changes over the course of the infection.

Some of the recurrent patients showed increased IL17/IFN-γ or IL17/Foxp3 phenotypes. Although expression of Foxp3, IL17 and IFN-γ was examined in separate wells, we cannot rule out that some circulating PMBC co-express either IL17 and IFN-γ or IL17 and Foxp3. The concept of T-cell plasticity extends back 20 years with murine data and cell line studies (Malmhäll et al., 2012). Malmhäll et al. (2012) described T-cell plasticity in asthma as well as healthy controls, suggesting two arms describe plasticity. Plastic cells either are not committed or are characterized by multiple transcription factors (Malmhäll et al., 2012). Recently, a novel IL17-secreting CD4+ cell co-expressing Foxp3 has been described in inflammatory bowel disease (Ueno et al., 2013). Functionally, the presence of this cell type appears to decrease ability of Treg to suppress T-cell proliferation. Our data indirectly demonstrate that recurrent patients’ circulating CD3+CD4+ cells can be either skewed towards a Foxp3/IL17, IL17/IFN-γ phenotype or driven towards a Th17 phenotype. The circulating PBMC phenotype from initial CDI patients appears driven towards committed end points.

Expression of Foxp3, both on CD3+ and CD3− cells, appears in the phenotype of all groups. The phenotypic difference between CDI clearance and recurrence is decreased co-expression of Foxp3 on the CD3− cells. A decrease is also seen in the number of circulating CD3− low SSC cells. The cell type remains unidentified, but due to lower granularity it could possibly be a B-cell. Circulating CD5−CD19+Foxp3+ cells have been described, but no function has been attributed to this cell type. Other regulatory B cells have been associated with IL-10 and transforming growth factor (TGF)-β production and induction of Treg (Berthelot et al., 2013; Noh et al., 2010; Vadasz et al., 2013). Further studies need to be done to identify the CD3−Foxp3+ population and determine its potential role in CDI clearance and recurrence.

Our study demonstrated phenotypic differences between CDI-positive and -negative patients, specifically within the CD3+ and CD3− populations. Plastic and pro-inflammatory (Foxp3/IL17, IFN-γ/IL17, IL17 skewed) CD3+CD4+.
phenotypes typified most CDI recurrent patients when compared with initial CDI, case or healthy control groups. Furthermore, at time of primary onset of CDI, those patients who clear initial infection and those patients who go on to become recurrent are phenotypically divergent. This small subgroup presented with circulating PBMC skewed towards a pro-inflammatory adaptive response with increased IFN-γ, IL17 and CD3\(^+\)CD4\(^+\) plasticity. The immune response to CDI is not static. Many of these PBMC phenotypic differences become less distinguishable in the known recurrent CDI subgroup. Successful CDI clearance was characterized by circulating PBMC composed of more CD3\(^-\)lymphocytes, greater numbers of cells which fall in the standard monocyte gate, a less plastic CD3\(^+\)CD4\(^+\) response, fewer IFN-γ-co-expressing lymphocytes and greater numbers of Foxp3\(^+\)-co-expressing CD3\(^-\) lymphocytes. Our pilot study further demonstrates the role of cellular inflammation in recurrent CDI and suggests the need for better patient stratification and alternate therapeutic choices, which may include combination therapy.

**ACKNOWLEDGEMENTS**

This work was supported by a Merck Sharp & Dohme Corporation Investigator Initiated study (IISP) proposal grant (38933) to B.Y. We thank Dr Madhuri Sopirala MD, UC division of Infectious Disease and Medical Director Department of Infection Control and Antimicrobial Stewardship UC Health, and Ms Carol Hamburg, UC Health Center infection preventionist, for their help in identifying and referring CDI patients; Dr David Bernstein MD and Dr Deb Ghosh PhD for the guidance and use of their flow cytometer.

**REFERENCES**


http://jmm.sgmjournals.org